Case File №
#VI-2026-0110
Anlv Biotechnology
Request Full Data Access to the VendorInvestigator database of peptide tests.
Exhibit I
Compounds on File
25 LINE ITEMS| Compound | Grade | Samples | Mean | Min | Max | Latest |
|---|---|---|---|---|---|---|
| Tirzepatide | C Okay | 7 | 7.4 | 4.9 | 10.0 | 31 Aug 2025 |
| Cagrilintide | X Unrated | 1 | 7.4 | 7.4 | 7.4 | 25 May 2026 |
| Tesamorelin | X Unrated | 1 | 6.7 | 6.7 | 6.7 | 25 May 2026 |
| Sermorelin | X Unrated | 1 | 8.3 | 8.3 | 8.3 | 25 May 2026 |
| 4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 | X N/A | 1 | 6.4 | 6.4 | 6.4 | 21 May 2025 |
| Boldenone Cypionate | X N/A | 1 | 5.9 | 5.9 | 5.9 | 2 Apr 2025 |
| Chonluten | X N/A | 1 | 7.6 | 7.6 | 7.6 | 8 Jul 2025 |
| Clenbuterol | X N/A | 1 | 7.3 | 7.3 | 7.3 | 14 Jan 2025 |
| EPO | X N/A | 1 | 7.1 | 7.1 | 7.1 | 25 Apr 2025 |
| GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | X N/A | 1 | 5.5 | 5.5 | 5.5 | 13 Feb 2025 |
| Hyaluronic acid | X N/A | 1 | 7.7 | 7.7 | 7.7 | 7 May 2025 |
| IGF-1 LR3 | X N/A | 1 | 5.7 | 5.7 | 5.7 | 2 Jul 2025 |
| Letrozole | X N/A | 1 | 9.2 | 9.2 | 9.2 | 9 Jun 2025 |
| Lipo-B 216mg | X N/A | 1 | 8.9 | 8.9 | 8.9 | 11 Jun 2025 |
| Ovagen | X N/A | 1 | 8.0 | 8.0 | 8.0 | 17 Dec 2024 |
| Oxytocin Acetate | X N/A | 1 | 4.3 | 4.3 | 4.3 | 17 Dec 2024 |
| P-2-P (phenyl-2-propanone / BMK) CAS 103-79-7 | X N/A | 1 | 4.0 | 3.9 | 3.9 | 24 Apr 2025 |
| Primobolan Oral (Methenolone Acetate) | X N/A | 1 | 8.7 | 8.7 | 8.7 | 2 Apr 2025 |
| PTD-DBM | X N/A | 1 | 6.1 | 6.1 | 6.1 | 9 Jun 2025 |
| Selank | X N/A | 1 | 5.7 | 5.7 | 5.7 | 3 Jun 2025 |
| Semaglutide Oral | X N/A | 1 | 5.7 | 5.7 | 5.7 | 24 Apr 2025 |
| Super Human Blend (Arginine+Ornithine+Citrulline+Lysine+Glutamine+Proline+Taurine+Carnitine+NAC) | X N/A | 1 | 10.0 | 10.0 | 10.0 | 17 Dec 2024 |
| Tesofensine | X N/A | 1 | 6.9 | 6.9 | 6.9 | 16 Mar 2025 |
| Test Suspension | X N/A | 1 | 5.2 | 5.2 | 5.2 | 13 Jun 2025 |
| Tirzepatide 30mg Pen Kit | X N/A | 1 | 6.2 | 6.2 | 6.2 | 21 May 2025 |
Exhibit II
Evidence Log
27 LABORATORY RETURNS| Filed | Compound | Score | Claimed | Found | Δ Qty | Purity | Batch № | Lab | Source |
|---|---|---|---|---|---|---|---|---|---|
| 25 May 2026 | 4-AP (4-anilino-piperidine / N-phenyl-4-piperidinamine) CAS 23056-29-3 | 5.1 B | 500g | 589.7g | +17.9% | 98.54% | l2jdiv | Lab G | Community |
| 25 May 2026 | Boldenone Cypionate | 7.0 A | 250mg/ml | 216.4mg/ml | -13.5% | 96.17% | hiqj4j | Lab C | Community |
| 25 May 2026 | Letrozole | 8.9 A | 100mg | 100.4mg | +0.4% | 97.61% | l7jg78 | Lab F | Public |
| 25 May 2026 | Primobolan Oral (Methenolone Acetate) | 10.0 A | 50mg | 54.2mg | +8.5% | 99.72% | 0yb86i | Lab D | Community |
| 24 May 2026 | Oxytocin Acetate | 4.0 C | 30mg | 33.1mg | +10.5% | 95.48% | t2yg2e | Lab F | Community |
| 24 May 2026 | Tesofensine | 7.8 A | 20mg | 22.6mg | +12.8% | 96.10% | s3ax2f | Lab C | Community |
| 23 May 2026 | Chonluten | 6.3 A | 50mg | 42.6mg | -14.8% | 97.33% | hx8375 | Lab F | Community |
| 23 May 2026 | Clenbuterol | 8.1 A | 10mg | 9.9mg | -0.7% | 97.62% | ufcaxl | Lab C | Public |
| 23 May 2026 | P-2-P (phenyl-2-propanone / BMK) CAS 103-79-7 | 4.0 C | 1g | 1.2g | +21.6% | 98.85% | wcm92z | Lab A | Community |
| 21 May 2026 | Tirzepatide | 8.0 A | 10mg | 10.3mg | +3.0% | 99.90% | (no batch ID) | Lab E | Public |
| 21 May 2026 | Tirzepatide | 4.9 D | 20mg | 25.7mg | +28.5% | 99.90% | (no batch ID) | Lab E | Public |
| 21 May 2026 | Test Suspension | 7.3 A | 100mg/ml | 100.7mg/ml | +0.7% | 98.21% | ctz6y1 | Lab E | Public |
| 21 May 2026 | Tirzepatide 30mg Pen Kit | 6.7 A | 5mg | 5.0mg | +0.1% | 95.51% | coudyv | Lab G | Public |
| 20 May 2026 | GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg | 4.5 C | 20mg | 19.0mg | -4.8% | 96.38% | p5u16b | Lab D | Public |
| 20 May 2026 | IGF-1 LR3 | 6.9 A | 30mg | 27.6mg | -8.0% | 99.92% | 0e9ut2 | Lab E | Public |
| 20 May 2026 | Super Human Blend (Arginine+Ornithine+Citrulline+Lysine+Glutamine+Proline+Taurine+Carnitine+NAC) | 10.0 A | 300mg/ml | 285.7mg/ml | -4.8% | 96.95% | nu2yq8 | Lab D | Community |
| 19 May 2026 | EPO | 8.6 A | 10mg | 9.7mg | -2.8% | 99.49% | 523bgy | Lab A | Community |
| 19 May 2026 | Lipo-B 216mg | 8.8 A | 200mg/ml | 235.5mg/ml | +17.7% | 99.50% | srwu0e | Lab B | Public |
| 29 Jan 2026 | PTD-DBM | 5.3 B | 5mg | 6.1mg | +21.5% | 99.68% | gjky34 | Lab F | Public |
| 7 Jan 2026 | Tirzepatide | 6.1 B | 40mg | 44.3mg | +10.8% | 99.80% | (no batch ID) | Lab G | Public |
| 29 Dec 2025 | Tirzepatide | 10.0 A | 10mg | 9.85mg | -1.5% | 99.95% | September 2025 | Lab E | Public |
| 12 Dec 2025 | Selank | 6.1 A | 30mg | 29.0mg | -3.5% | 96.10% | 25048g | Lab E | Public |
| 5 Dec 2025 | Semaglutide Oral | 5.2 B | 10mg | 9.4mg | -5.6% | 96.91% | ds98pp | Lab F | Public |
| 4 Nov 2025 | Ovagen | 9.1 A | 2mg | 1.7mg | -12.9% | 95.76% | 49wb5l | Lab B | Public |
| 23 Oct 2025 | Tirzepatide | 5.8 C | 60mg | 62.3mg | +3.8% | 98.81% | (no batch ID) | Lab E | Public |
| 17 Oct 2025 | Hyaluronic acid | 6.0 A | 30mg | 31.3mg | +4.2% | 96.36% | 15t7u3 | Lab E | Public |
| 31 Aug 2025 | Tirzepatide | 8.0 A | 20mg | 19.4mg | -3.0% | 99.95% | (no batch ID) | Lab E | Public |
— END OF EVIDENCE LOG —